IQVIA drops nearly 6% as guidance overhang and earnings timing drive selling
IQVIA shares fell about 6% to $160.06 as investors positioned ahead of its next earnings update and focused on prior 2026 profit guidance that came in below consensus. The stock has been under pressure since the Feb. 5, 2026 outlook highlighted higher interest expense as a headwind to EPS.
1) What’s moving the stock today
IQVIA Holdings (IQV) slid roughly 5.9% to $160.06 in Thursday trading, extending a pullback as the market looked ahead to the company’s next earnings update and continued to discount its 2026 outlook. Traders have been pointing back to the most recent full-year guidance framework, where the company’s 2026 adjusted EPS range was set at $12.55–$12.85 and was widely viewed as light versus prior expectations, with higher interest expense cited as a factor weighing on the profit outlook. (ir.iqvia.com)
2) The near-term catalyst investors are watching
IQVIA is approaching its next quarterly results window, which can amplify volatility in both the shares and options as investors recalibrate positioning ahead of the print and any guidance commentary. Market calendars currently point to early May 2026 for the company’s next reported quarter, keeping attention on whether management reiterates or adjusts the full-year revenue and earnings ranges issued with the last annual results update. (marketbeat.com)
3) Why the guidance remains a pressure point
The key debate is whether demand and bookings momentum can translate into enough margin and cash flow to offset financing costs and other expense items embedded in the 2026 plan. The company’s February guidance reset emphasized that interest expense had stepped up following financing activity, a narrative that has lingered as a valuation and sentiment headwind for a highly leveraged, acquisition-active services model. (tikr.com)
4) What to watch next
Investors will be focused on any changes to the 2026 adjusted EPS range, updates on revenue conversion from backlog, and commentary on R&D services demand trends across large pharma and biotech. Any incremental disclosure around capital allocation—including pace of share repurchases versus debt paydown—could also influence near-term trading given the market’s sensitivity to interest-cost pressure. (s201.q4cdn.com)